Janssen Therapeutics, Division of Janssen Products, has received accelerated approval for Sirturo (bedaquiline) tablets from the US FDA to treat adult pulmonary multi-drug resistant tuberculosis (MDR-TB) patients.

The approval of Sirturo as part of combination therapy is based on the surrogate endpoint of time to sputum culture conversion.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Johnson & Johnson pharmaceuticals chief scientific officer and worldwide chairman Dr Paul Stoffels said that Sirturo is the first TB therapy in 40 years with a new mechanism of action.

“The accelerated approval of SIRTURO is a significant step in the fight against MDR-TB, which is a more difficult to treat form of TB that affects approximately 630,000 people in the world and is on the rise in many areas worldwide,” Stoffels said.

The diarylquinoline antimycobacterial drug should be administered by directly observed therapy.

The indication is based on analysis of time to sputum culture conversion from two Phase II trials, TMC207-C208 Study 1 and Study 2, conducted in patients with pulmonary MDR-TB.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sirturo was developed to inhibit mycobacterial adenosine 5′ triphosphate synthase enzyme, which is key for energy production in Mycobacterium tuberculosis.

New Jersey Medical School Global Tuberculosis Institute executive director Dr Lee Reichman said; “This is the first time a new drug is being introduced specifically for MDR-TB, for which the current needs are so great.”

The safety and efficacy of Sirturo for the treatment of latent infection due to Mycobacterium tuberculosis, for the treatment of drug-sensitive TB were not been established.